164 related articles for article (PubMed ID: 37622756)
21. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
[TBL] [Abstract][Full Text] [Related]
22. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
[TBL] [Abstract][Full Text] [Related]
23. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
Phelps TE; Yilmaz EC; Harmon SA; Belue MJ; Shih JH; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
Abdom Radiol (NY); 2023 Mar; 48(3):1079-1089. PubMed ID: 36526922
[TBL] [Abstract][Full Text] [Related]
24. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
[TBL] [Abstract][Full Text] [Related]
25. Transperineal multiparametric magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy combined with standard template improves perineural invasion detection.
Wu CL; Kim M; Wu S; Lin SX; Crotty RK; Harisinghani M; Feldman AS; Dahl DM
Hum Pathol; 2021 Nov; 117():101-107. PubMed ID: 34461132
[TBL] [Abstract][Full Text] [Related]
26. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
[TBL] [Abstract][Full Text] [Related]
27. Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.
Freifeld Y; Xi Y; Passoni N; Woldu S; Hornberger B; Goldberg K; Bagrodia A; Raj G; Margulis V; Cadeddu JA; Lotan Y; Francis F; Pedrosa I; G Roehrborn C; Costa DN
Urol Oncol; 2019 Jan; 37(1):57-62. PubMed ID: 30446460
[TBL] [Abstract][Full Text] [Related]
28. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
29. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
Maxeiner A; Nest AM; Stephan C; Cash H; Baur ADJ; Fischer T; Kilic E; Piper SK; Nowak CP; Busch J; Miller K; Mang J
Urol Int; 2020; 104(3-4):205-213. PubMed ID: 31801153
[TBL] [Abstract][Full Text] [Related]
30. [Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].
Kesch C; Radtke JP; Distler F; Boxler S; Klein T; Hüttenbrink C; Hees K; Roth W; Roethke M; Schlemmer HP; Hohenfellner M; Hadaschik BA
Urologe A; 2016 Aug; 55(8):1071-7. PubMed ID: 27168038
[TBL] [Abstract][Full Text] [Related]
31. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
32. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
33. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
[TBL] [Abstract][Full Text] [Related]
34. Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy.
Shen WW; Cui LG; Ran WQ; Sun Y; Jiang J; Pei XL; Chen W
Ultrasound Med Biol; 2020 May; 46(5):1197-1207. PubMed ID: 32107089
[TBL] [Abstract][Full Text] [Related]
35. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1.
Apfelbeck M; Pfitzinger P; Bischoff R; Rath L; Buchner A; Mumm JN; Schlenker B; Stief CG; Chaloupka M; Clevert DA
Clin Hemorheol Microcirc; 2020; 76(4):503-511. PubMed ID: 33337358
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology.
Cai Q; Costa DN; Metter CK; Goldberg K; Roehrborn CG; Cadeddu J; Pedrosa I; Meng X; Mostardeiro TR; Shah RB
Urol Oncol; 2022 Oct; 40(10):452.e1-452.e8. PubMed ID: 36008255
[TBL] [Abstract][Full Text] [Related]
37. Early experience with multiparametric magnetic resonance imaging-targeted biopsies under visual transrectal ultrasound guidance in patients suspicious for prostate cancer undergoing repeated biopsy.
Boesen L; Noergaard N; Chabanova E; Logager V; Balslev I; Mikines K; Thomsen HS
Scand J Urol; 2015 Feb; 49(1):25-34. PubMed ID: 24922550
[TBL] [Abstract][Full Text] [Related]
38. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
39. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
Mannaerts CK; Kajtazovic A; Lodeizen OAP; Gayet M; Engelbrecht MRW; Jager GJ; Wijkstra H; de Reijke TM; Beerlage HP
Urol Oncol; 2019 May; 37(5):298.e1-298.e9. PubMed ID: 30660493
[TBL] [Abstract][Full Text] [Related]
40. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.
Arsov C; Rabenalt R; Blondin D; Quentin M; Hiester A; Godehardt E; Gabbert HE; Becker N; Antoch G; Albers P; Schimmöller L
Eur Urol; 2015 Oct; 68(4):713-20. PubMed ID: 26116294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
